Haemostasis biomarkers and risk of intracerebral haemorrhage in the REasons for Geographic and Racial Differences in Stroke Study

Summary

Pathologic alterations in haemostasis cause bleeding disorders, but it is unknown if variation within the normal range relates to intracerebral haemorrhage (ICH) risk. It was our objective to assess the prospective associations of haemostasis biomarkers with ICH risk. The REasons for Geographic and Racial Differences in Stroke study (REGARDS) recruited 30,239 U. S. individuals aged ≥45 years. ICH was ascertained through biannual telephone contact and review of deaths followed by medical record evaluation. Haemostasis biomarkers (factor VIII (FVIII), factor IX (FIX), factor XI (FXI), fibrinogen, protein C, and D-dimer) were measured in a case cohort study consisting of ICH and a 1,104 person cohort random sample. The hazard ratio (HR) and 95 % confidence interval (CI) by biomarker were estimated using Cox models and adjusted for ICH risk factors. Individuals with a prior history of stroke, ICH or on warfarin were excluded. Over a median 5.8 years 66 ICH occurred. Fibrinogen, FVIII, FXI, and protein C were not associated with ICH risk in any analysis. Lower FIX increased risk of ICH with the bottom versus the top tertile of FIX associated with an HR of 5.68 (95 % CI 2.30, 14.05). D-dimer demonstrated a non-linear relationship with a potential threshold effect with increased risk only in the top 5th percentile (HR 3.22; 95 % CI 1.01, 10.31; p_non-linear = 0.04).In conclusion, low FIX levels within the normal range were associated with increased ICH risk. These data suggest non-pathologic alterations in haemostasis impact intracranial bleeding risk.

Keywords

Cerebral haemorrhage - cohort studies - continental population groups - epidemiology - haemostasis

• References

• 1 Sturgeon JD, Folsom AR, Longstreth Jr. WT. et al. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007; 38: 2718-2725.
• 2 Rincon F, Mayer SA. The epidemiology of intracerebral hemorrhage in the United States from 1979 to 2008. Neurocrit Care 2013; 19: 95-102.
• 3 Howard G, Cushman M, Howard VJ. et al. Risk factors for intracerebral hemorrhage: the REasons for geographic and racial differences in stroke (REGARDS) study. Stroke 2013; 44: 1282-1287.
• 4 Woo D, Sauerbeck LR, Kissela BM. et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002; 33: 1190-1195.
• 5 Feldmann E, Broderick JP, Kernan WN. et al. Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke 2005; 36: 1881-1885.
• 6 Ariesen MJ, Claus SP, Rinkel GJ. et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34: 2060-2065.
• 7 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
• 8 Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44: 62-69.
• 9 Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113: 2878-2887.
• 10 Howard G, Cushman M, Kissela BM. et al. Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke 2011; 42: 3369-3375.
• 11 Howard VJ, Cushman M, Pulley L. et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiol 2005; 25: 135-143.
• 12 Gillett SR, Boyle RH, Zakai NA. et al. Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort. Clin Biochem 2014; 47: 243-246.
• 13 Barlow WE, Ichikawa L, Rosner D. et al. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-1172.
• 14 Kulathinal S, Karvanen J, Saarela O. et al. Case-cohort design in practice - experiences from the MORGAM Project. Epidemiol Perspect Innov 2007; 04: 15.
• 15 Cushman M, Judd SE, Howard VJ. et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke 2014; 45: 1646-1650.
• 16 Zakai NA, Judd SE, Alexander K. et al. ABO blood type and stroke risk: the REasons for Geographic And Racial Differences in Stroke Study. J Thromb Haemost 2014; 12: 564-570.
• 17 Quinones-Hinojosa A, Gulati M, Singh V. et al. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 2003; 15: pE3.
• 18 Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH. et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52-56.
• 19 Woo D, Falcone GJ, Devan WJ. et al. Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. Am J Hum Genet 2014; 94: 511-521.
• 20 Hirsh J, Dalen J, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl. 01) 8S-21S.
• 21 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 22 Investigators E-P, Buller HR, Prins MH. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
• 23 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
• 24 Adams NB, Lutsey PL, Folsom AR. et al. Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost 2013; 11: 1078-1084.
• 25 Peralta CA, Shlipak MG, Judd S. et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. J Am Med Assoc 2011; 305: 1545-1552.
• 26 Zakai NA, Katz R, Jenny NS. et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007; 05: 1128-1135.
• 27 Di Castelnuovo A, Agnoli C, de Curtis A. et al. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPI-COR Study. Thromb Haemost 2014; 112: 941-946.
• 28 Warren HS, Suffredini AF, Eichacker PQ. et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 1027-1030.
• 29 Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314: 1298-1304.
• 30 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
• 31 Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140: 378-384.
• 32 de Tezanos Pinto M, Fernandez J, Perez Bianco PR. Update of 156 episodes of central nervous system bleeding in hemophiliacs. Haemostasis 1992; 22: 259-267.
• 33 Peyvandi F, Palla R, Menegatti M. et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-621.
• 34 Casini A, Blondon M, Lebreton A. et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125: 553-561.
• 35 Buller HR, Bethune C, Bhanot S. et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372: 232-240.
• 36 Rasche H. Haemostasis and thrombosis: an overview. Eur Heart J Suppl 2001; 03 (Q) Q3-Q7.